Literature DB >> 19857681

Results of treatment of acute liver failure patients with use of the prometheus FPSA system.

M Grodzicki1, M Kotulski, D Leonowicz, K Zieniewicz, M Krawczyk.   

Abstract

OBJECTIVE: Herein we have presented the results of treatment of acute liver failure (ALF) patients with the use of the Prometheus FPSA dialysis system.
MATERIALS AND METHODS: To January 2009, we performed 278 FPSA procedures in 114 patients, including 52 experience and ALF. The patients who underwent the FPSA procedure consisted of 32 women and 20 men of overall mean age of 33 +/- 12 years. The causes of ALF were: Wilson's disease (n = 15), unknown origin ALF (n = 11), amanita phalloides intoxication (n = 7), paracetamol intoxication (n = 8), acute hepatitis B virus (HBV)/hepatitis C virus (HCV) infection (n = 7), liver insufficiency after parenchymal resection (n = 2) drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome (n = 1), rabdomyolysis (n = 1), or primary nonfunction (PNF) after orthotopic liver transplantation (OLT) (n = 1). All procedures were performed using the Prometheus 4008H Fresenius Medical Care liver support system. The average number of treatments per patient was 2.41 and the average time for each FPSA treatment was 6.3 hours. The average heparin dose used during the procedure was 750 IU/h.
RESULTS: After the whole treatment regimen, we observed significant improvements in the biochemical results. The average concentrations improved: serum ammonia (before 249.2 mug/dL versus after 109.7 mug/dL); serum bilirubin (before 21.53 mg/dL versus after 8.81 mg/dL), serum aspartate aminotransferase (AST; before 2456.4 U/L versus after 1068.8 U/L); serum alanine aminotransferase (ALT; before 2958.2 U/L versus after 1595.8 U/L); serum urea (before 58.5 mg/dL versus after 21.1 mg/dL); serum creatinine (before 2.9 mg/dL versus after 1.7 mg/dL); and pH value (before 7.11 versus after 7.32). After Prometheus treatment OLT was performed in 33 patients. Among the 28 who survived (53.8%), 22 underwent OLT and 6 did not have OLT. Among the 24 patients who died (46.2%), 13 were before OLT and 11 after OLT.
CONCLUSION: The Prometheus 4008H Fresenius Medical Care Liver support system was useful method of detoxification for patients with ALF, serving as an element of pretransplantation care.

Entities:  

Mesh:

Year:  2009        PMID: 19857681     DOI: 10.1016/j.transproceed.2009.08.024

Source DB:  PubMed          Journal:  Transplant Proc        ISSN: 0041-1345            Impact factor:   1.066


  6 in total

1.  A new treatment strategy for acute liver failure.

Authors:  Kazuhiro Kotoh; Masaki Kato; Motoyuki Kohjima; Makoto Nakamuta; Munechika Enjoji
Journal:  World J Hepatol       Date:  2010-11-27

Review 2.  Liver transplantation in acute liver failure: A challenging scenario.

Authors:  Manuel Mendizabal; Marcelo Oscar Silva
Journal:  World J Gastroenterol       Date:  2016-01-28       Impact factor: 5.742

3.  Inhibition of 5-lipoxygenase pathway attenuates acute liver failure by inhibiting macrophage activation.

Authors:  Lu Li; Yi-Rong Liu; Shan Gao; Jun-Feng Li; Shan-Shan Li; Dan-Dan Zhang; Shuang Liu; Li Bai; Su-Jun Zheng; Zhong-Ping Duan; Min Qi; Yu Chen
Journal:  J Immunol Res       Date:  2014-06-01       Impact factor: 4.818

4.  Prometheus therapy for the treatment of acute liver failure in patients after cardiac surgery.

Authors:  Ekaterina Komardina; Michael Yaroustovsky; Marina Abramyan; Marina Plyushch
Journal:  Kardiochir Torakochirurgia Pol       Date:  2017-12-20

Review 5.  Artificial liver support systems: what is new over the last decade?

Authors:  Juan José García Martínez; Karim Bendjelid
Journal:  Ann Intensive Care       Date:  2018-11-15       Impact factor: 6.925

6.  Evaluation of the Hepa Wash® treatment in pigs with acute liver failure.

Authors:  Ahmed Al-Chalabi; Edouard Matevossian; Anne-K V Thaden; Peter Luppa; Albrecht Neiss; Tibor Schuster; Zejian Yang; Catherine Schreiber; Patrick Schimmel; Ewald Nairz; Aurel Perren; Peter Radermacher; Wolfgang Huber; Roland M Schmid; Bernhard Kreymann
Journal:  BMC Gastroenterol       Date:  2013-05-13       Impact factor: 3.067

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.